Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Chem Commun (Camb) ; 54(39): 4947-4950, 2018 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-29700524

RESUMEN

We herein present pioneering studies to reveal that excitation-wavelength-dependent photoluminescence properties of fluorescent silicon nanoparticles (SiNPs) can be realized by rationally designing surface ligands, i.e., several kinds of oxidized indole derivatives. The resultant ligand-decorated SiNPs exhibit strong fluorescence, with significant excitation-wavelength-dependent emissive shifting from ∼420 nm to ∼550 nm. Taking advantage of their unique optical merits, we further exploit the resultant ligand-decorated SiNPs as novel fluorescent labels for anti-counterfeiting and cell imaging.

2.
J Microbiol Immunol Infect ; 48(6): 597-603, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24863497

RESUMEN

PURPOSE: To preliminarily evaluate the immunogenicity and efficacy of the recombinant tuberculosis vaccine AEC/BC02 in which Ag85b and fusion protein ESAT6-CFP10 were combined with bacillus Calmette-Guérin CpG and an aluminum salt-based adjuvant system. METHODS: Groups of BALB/c mice were immunized intramuscularly three times at 10-day intervals with AEC/BC02 or the adjuvant alone and the vaccine-induced cell-mediated immune responses were evaluated. The efficacy of AEC/BC02 was evaluated in two guinea pig models, one a model of prevention and the other a model of latent infection. RESULTS: The AEC/BC02 vaccine induced strong cellular immune responses characterized by a high frequency of antigen-specific interferon-γ-secreting T cells in mice at different time points after the last vaccination. In the preventive model of guinea pig, AEC/BC02 did not protect against Mycobacterium tuberculosis as a pre-exposure vaccine. However, in a latent infection model of guinea pig, it effectively controlled the reactivation of M. tuberculosis and lowered the bacterial load in the lung and spleen. CONCLUSION: These results indicate AEC/BC02 can protect against reactivation of latent infection and may function as a therapeutic vaccine.


Asunto(s)
Antígenos Bacterianos/inmunología , Tuberculosis Latente/inmunología , Mycobacterium tuberculosis/inmunología , Células TH1/inmunología , Vacunas contra la Tuberculosis/inmunología , Vacunas Sintéticas/inmunología , Animales , Anticuerpos Antibacterianos/inmunología , Vacuna BCG/inmunología , Carga Bacteriana/inmunología , Modelos Animales de Enfermedad , Cobayas , Interferón gamma/inmunología , Interferón gamma/metabolismo , Tuberculosis Latente/microbiología , Tuberculosis Latente/prevención & control , Pulmón/microbiología , Ratones , Ratones Endogámicos BALB C , Bazo/microbiología , Vacunación
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda